Ortataxel
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
(3aS,4R,7R,8aS,9S,10aR,12aS,13S,13aS)-7,12a-bis(acetyloxy)-4-({(2R,3S)-3-[tert-butoxycarbonyl)amino]-2-hydroxy-5-methylhexanoyl}oxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano[1,3]dioxolo[8,9]cyclodeca[1,2-d][1]benzoxet-13-yl benzoate
|
|
Identifiers | |
CAS Number | 186348-23-2 |
ATC code | none |
PubChem | CID: 10557575 |
ChemSpider | 5293609 |
UNII | 8H61Y4E29N |
Chemical data | |
Formula | C44H57NO17 |
Molecular mass | 871.92 g/mol |
|
|
|
|
(verify) |
Ortataxel is a drug used in chemotherapy. As of June 2009[update], Spectrum Pharmaceuticals has the drug is in a Phase 2 clinical trial.
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing potentially dated statements from June 2009
- Mitotic inhibitors
- Benzoates
- Carbamates
- Alcohols
- Ketones
- Acetate esters
- Taxanes
- Antineoplastic and immunomodulating drug stubs